Access | Reimbursement Support | Care

Stemline ARC™ Care

Manage eligible patients’ treatment with personalized care, support, and resources available throughout their journey

A cancer diagnosis can be overwhelming. Stemline ARC offers care, resources, tools, and personalized support to help your patients and their families navigate the treatment journey. Support includes:

Nurse Advocates

Stemline ARC Nurse Advocates are oncology certified registered nurses. Patients and their caregivers are supported by a dedicated Nurse Advocate who will provide personalized education and information about disease state and ELZONRIS™ (tagraxofusp-erzs) Injection for Intravenous (IV) Use, including helpful tools and resources. The Nurse Advocate will establish and maintain contact with patients throughout their ELZONRIS Injection for IV Use treatment journey, with a welcome call and letter, followed by strategically timed telephone outreach during each cycle. Providers will also receive notification when a newly enrolled patient has been welcomed into the program by the Nurse Advocate.

What to expect from your Nurse Advocate

'Before' calendar icon

Before treatment starts, patients will receive several calls from their Nurse Advocate to review support services including financial assistance, education, appointment confirmation, and insurance verification.

'During' calendar icon

During treatment cycles, Nurse Advocates will call with treatment updates, reminders, and ongoing education.

'After' calendar icon

Following each treatment cycle, Nurse Advocates will call patients to provide additional guidance, including support regarding their transition from inpatient to outpatient treatment, helpful resources, and ongoing education.

After treatment, Nurse Advocates will continue making follow-up calls to provide additional education, guidance, and resources.

Caregiving RESOURCES

Caring for a loved one who is diagnosed with cancer can be daunting. Listed below are organizations that may be able to help educate and support your patients and the family members and friends who are caring for them. Visit these websites for helpful resources.

American Association of Retired Persons (AARP)—A nonprofit, nonpartisan organization, with a membership of more than 38 million, that makes your patients’ goals and dreams possible, strengthens communities, and fights for the issues that matter most to families, such as healthcare, employment security, and retirement planning. www.aarp.org/caregiving

American Cancer Society Hope Lodge—For cancer patients receiving treatment more than 40 miles away from home, as well as their caregivers, the Hope Lodge network provides a home away from home. www.cancer.org/treatment/support-programs-and-services/patient-lodging/hope-lodge

CancerCare®—Offers professional support services, information, and resources for caregivers and their loved ones free of cost. www.cancercare.org/tagged/caregiving

Cancer Support Community (CSC)—As the largest professionally led nonprofit network of cancer support worldwide, CSC annually provides more than $50 million in support services to patients and their loved ones at no cost. CSC consists of a global network of 175 locations, including CSC and Gilda's Club centers, healthcare partnerships, and satellite locations. 1-888-793-9355. www.cancersupportcommunity.org

Caregiver Action Network (CAN)—A nationwide nonprofit organization delivering free support services, education, and other resources to caregivers. www.caregiveraction.org

Caring From a Distance—A nonprofit organization that understands the challenges associated with long-distance care and provides local help and useful tools to coordinate care, benefits, and services. www.cfad.org

United States Department of Labor—For information on disability benefits, civil rights, community life, education, and employment. Find the US Social Security administration disability benefit eligibility screening tool, information, and assistance. www.disability.gov

Family Caregiver Alliance (FCA)—The first US community-based nonprofit organization to deliver long-term care at home through its national-, state-, and local-level support services. www.caregiver.org

Health Insurance Marketplace—Enroll in a health plan, determine if you’ve had a life-changing event qualifying you for benefits, or just investigate ways to save money on healthcare expenses. 1-800-318-2596. www.healthcare.gov

Healthcare Hospitality Network—A nationwide network of nearly 200 nonprofit organizations providing lodging and support services to patients, families, and loved ones receiving medical treatment in locations far from their home communities. www.hhnetwork.org

Joe's House—A nonprofit organization helping cancer patients and their families find a place to stay when receiving treatment away from home. www.joeshouse.org

Centers for Medicare & Medicaid Services (CMS): Medicare—Offers outreach and education resources specifically for caregivers assisting a patient who is aged 65 years and older (or younger with certain disabilities) and who may be eligible for government-sponsored insurance. Topics include billing, navigating Medicare, support groups, and care options. www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Caregiver.html

National Alliance for Caregiving—Focuses on supporting caregivers through international advocacy, policy analysis, ongoing research, and public awareness of barriers facing caregivers. www.caregiving.org

Well Spouse Association—Advocates for caregivers of a spouse or partner who is chronically ill and/or disabled, offering peer-to-peer support and education about the daily challenges of being a "well" spouse. 1-800-838-0879. www.wellspouse.org

The organizations listed above are independent from Stemline. This information is provided as a resource for patients and is not an endorsement or guarantee of assistance.

Educational Resources

Once a treatment plan has been established, many logistics must fall into place. Below are links to resources for educational support.

CancerCare®—Offers professional support services, information, and resources for caregivers and their loved ones free of cost. www.cancercare.org/tagged/caregiving

Cancer Financial Assistance Coalition (CFAC)—A support network committed to tackling the financial (and practical) barriers of cancer treatment. www.cancerfac.org

Cancer.Net—Provides timely, comprehensive, oncologist-approved information from the American Society of Clinical Oncology, with support from the Conquer Cancer Foundation. www.cancer.net/navigating-cancer-care

Cancer Support Community (CSC)—As the largest professionally led nonprofit network of cancer support worldwide, CSC annually provides more than $50 million in support services to patients and their loved ones at no cost. CSC consists of a global network of 175 locations, including CSC and Gilda's Club centers, healthcare partnerships, and satellite locations. 1-888-793-9355. www.cancersupportcommunity.org

Leukemia and Lymphoma Society (LLS)—Provides free blood cancer information and support to patients, families, survivors, and healthcare professionals. LLS also provides funding for groundbreaking research and advocates on the state and federal levels for policies that remove barriers to care for patients with blood cancer. www.lls.org

MyLifeLine—Offers a free online communication platform where patients and caregivers can connect with each other and find key web resources to support the healing process. www.mylifeline.org

National Alliance for Caregiving—Focuses on supporting caregivers through international advocacy, policy analysis, ongoing research, and public awareness of barriers facing caregivers. www.caregiving.org

The organizations listed above are independent from Stemline. This information is provided as a resource for patients and is not an endorsement or guarantee of assistance.

Food and Nutrition RESOURCES

Explore helpful organizations for food delivery. Options will continue to be updated as they become available.

Meals on Wheels America—Specializes in delivering nutritious meals to high-risk seniors and other people with disabilities, and providing a daily dose of human contact along the way. www.mealsonwheelsamerica.org

The organizations listed above are independent from Stemline. This information is provided as a resource for patients and is not an endorsement or guarantee of assistance.

Transportation Support RESOURCES

Sometimes patients need help getting where they need to go. The organizations listed below may provide practical support with finding transportation when needed.

The Air Care Alliance (ACA)—A nonprofit public benefit 501(c)(3) organization incorporated in the state of California to facilitate charitable flights through cooperation between aviation associations and governmental agencies. 1-888-260-9707. www.aircarealliance.org

Air Charity Network—Coordinates free flights with volunteer pilots for your patients requiring long-distance doctor appointments, surgery, or treatment. 1-877-621-7177. www.aircharitynetwork.org

American Cancer Society (ACS)—Provides your patients and their caregivers with 24/7 support throughout the treatment process, from free lodging and transportation to informative resources and emotional support. 1-800-227-2345. www.cancer.org

Angel Flight—A nonprofit charitable organization that arranges free medically related flight services to individuals in financial need and healthcare organizations. 1-918-749-8992. www.angelflight.com

Angel Wheels™—A nonprofit charity offering nonemergency, long-distance ground transportation to patients who are disabled, in financial need, and require treatment typically no more than 300 miles away. Exceptions may be made, particularly if travel is required for daily treatment. www.angelwheels.org

Corporate Angel Network—A charitable organization dedicated to securing empty seats on private and corporate flights for eligible patients requiring in-hospital specialized treatment. There is no cost for this service. 1-866-328-1313. www.corpangelnetwork.org

Fisher House Foundation—Provides free housing at military bases and VA medical centers worldwide for family members of military or veterans to live comfortably while their loved one is hospitalized. 1-888-294-8560. www.fisherhouse.org

National Patient Travel Center—Helps patients in need with air transportation by providing commercial airline tickets and volunteer pilots, and with ground transportation, by providing gas cards and bus and train tickets. 1-800-296-1217. www.patientadvocate.org

Patient AirLift Services—Arranging free air transportation for patients who need to travel for diagnosis, treatment, or follow-up. www.palservices.org

The organizations listed above are independent from Stemline. This information is provided as a resource for patients and is not an endorsement or guarantee of assistance.

For questions or more information about Stemline ARC, call 1-833-4-STEMLINE (1-833-478-3654)
from 8:00 AM to 8:00 PM ET, Monday through Friday.

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • ELZONRIS can cause capillary leak syndrome (CLS), which may be life-threatening or fatal if not properly managed. The overall incidence of CLS in clinical trials was 55% in patients receiving ELZONRIS, including 46% in Grades 1 or 2, 6% in Grade 3, 1% in Grade 4, and 2 fatal events. Common signs and symptoms (incidence ≥ 20%) associated with CLS that were reported during treatment with ELZONRIS include hypoalbuminemia, edema, weight gain, and hypotension
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is ≥ 3.2 g/dL
  • During treatment with ELZONRIS, ensure that serum albumin levels are ≥ 3.5 g/dL and have not been reduced by ≥ 0.5 g/dL from the albumin value measured prior to dosing initiation of the current cycle. Monitor serum albumin levels prior to the initiation of each dose or more often as indicated clinically thereafter. Additionally, assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema including pulmonary edema, hypotension, or hemodynamic instability
  • Counsel patients to seek immediate medical attention should signs or symptoms of CLS occur at any time

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. Grade 3 or higher events were reported in 10% of patients in clinical trials. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur. If the reaction is severe, discontinue ELZONRIS permanently

Hepatotoxicity

  • Elevations in liver enzymes can occur with ELZONRIS. Grade 3 or higher elevations in liver enzymes occurred in approximately 40% of patients in clinical trials
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Temporarily withhold ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal (ULN) and resume treatment upon normalization or when resolved

ADVERSE REACTIONS:

The most common adverse reactions in the clinical trials (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose, ALT, and AST.


Please see full Prescribing Information, including Boxed WARNING.


To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION

INDICATION

  • ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older

IMPORTANT SAFETY INFORMATION

Boxed WARNING: CAPILLARY LEAK SYNDROME

  • Capillary Leak Syndrome (CLS), which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended

WARNINGS AND PRECAUTIONS

Capillary Leak Syndrome

  • ELZONRIS can cause capillary leak syndrome (CLS), which may be life-threatening or fatal if not properly managed. The overall incidence of CLS in clinical trials was 55% in patients receiving ELZONRIS, including 46% in Grades 1 or 2, 6% in Grade 3, 1% in Grade 4, and 2 fatal events. Common signs and symptoms (incidence ≥ 20%) associated with CLS that were reported during treatment with ELZONRIS include hypoalbuminemia, edema, weight gain, and hypotension
  • Before initiating therapy with ELZONRIS, ensure that the patient has adequate cardiac function and serum albumin is ≥ 3.2 g/dL
  • During treatment with ELZONRIS, ensure that serum albumin levels are ≥ 3.5 g/dL and have not been reduced by ≥ 0.5 g/dL from the albumin value measured prior to dosing initiation of the current cycle. Monitor serum albumin levels prior to the initiation of each dose or more often as indicated clinically thereafter. Additionally, assess patients for other signs or symptoms of CLS, including weight gain, new onset or worsening edema including pulmonary edema, hypotension, or hemodynamic instability
  • Counsel patients to seek immediate medical attention should signs or symptoms of CLS occur at any time

Hypersensitivity Reactions

  • ELZONRIS can cause severe hypersensitivity reactions. Grade 3 or higher events were reported in 10% of patients in clinical trials. Monitor patients for hypersensitivity reactions during treatment with ELZONRIS. Interrupt ELZONRIS infusion and provide supportive care as needed if a hypersensitivity reaction should occur. If the reaction is severe, discontinue ELZONRIS permanently

Hepatotoxicity

  • Elevations in liver enzymes can occur with ELZONRIS. Grade 3 or higher elevations in liver enzymes occurred in approximately 40% of patients in clinical trials
  • Monitor alanine aminotransferase (ALT) and aspartate aminotransferase (AST) prior to each infusion with ELZONRIS. Temporarily withhold ELZONRIS if the transaminases rise to greater than 5 times the upper limit of normal (ULN) and resume treatment upon normalization or when resolved

ADVERSE REACTIONS:

The most common adverse reactions in the clinical trials (incidence ≥ 30%) are capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities (incidence ≥ 50%) are decreases in albumin, platelets, hemoglobin, calcium, sodium, and increases in glucose, ALT, and AST.


Please see full Prescribing Information, including Boxed WARNING.


To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.